Ireland's Jazz Pharmaceuticals beats Q4 revenue, profit estimates

Jazz Pharmaceuticals

24/02/2026 21:37

Overview

Ireland-based biopharma's Q4 revenue rose 10% yr/yr, beating analyst expectations

Adjusted EPS for Q4 beat analyst expectations

Company expects 2026 revenue of $4.25 to $4.50 bln

Outlook

Jazz Pharmaceuticals expects 2026 total revenue of $4.25 to $4.50 bln

Company anticipates double-digit growth in epilepsy and oncology franchises in 2026

Jazz plans sBLA submission for zanidatamab in 1Q26, potential launch in 2H26

Result Drivers

XYWAV SALES - Xywav net product sales increased 12% to $1.7 bln in 2025, driven by strong new patient growth

MODEYSO LAUNCH - Modeyso generated $37 mln in revenue in its first full quarter on the market

Company press release: ID:nPn56DHWZa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$1.20 bln
$1.17 bln (13 Analysts)
Q4 Adjusted EPS
Beat
$6.64
$6.52 (14 Analysts)
Q4 EPS
$3.21
Q4 Adjusted Net Income
Beat
$420.89 mln
$405.88 mln (13 Analysts)
Q4 Net Income
$203.45 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Jazz Pharmaceuticals PLC is $219.50, about 26.7% above its February 23 closing price of $173.25

The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 7 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)